5-Amino-1MQ benefits are metabolic rather than appetite-driven, the reported side effects are mild but thinly documented, and dosage figures in circulation contradict each other by a factor of more than a hundred depending on which vendor you read. That last problem is the reason this guide leads with sourcing rather than with mechanism. Before anything else: despite being sold on peptide sites and shelved next to injectable peptides, 5-Amino-1MQ is not a peptide. It is a small molecule.
Key Takeaways
- 5-Amino-1MQ (5-amino-1-methylquinolinium) is a synthetic small molecule, not a chain of amino acids. Calling it a peptide is a marketing convention, not chemistry.
- It selectively inhibits nicotinamide N-methyltransferase (NNMT), an enzyme that consumes nicotinamide and SAM and is overexpressed in white adipose tissue in obesity.
- Evidence is preclinical. Cell work and rodent models are consistent, and no published human clinical trial supports any of the body composition claims.
- Reported research ranges split into two incompatible camps: oral protocols around 25 to 100 mg per day, and injectable protocols around 150 to 500 mcg per day.
- Because it is a small molecule rather than a peptide, standard peptide purity testing does not apply cleanly, which makes vendor documentation harder to interpret and more important to check.
Why the Dose Numbers Disagree, and What That Tells You
Start with the discrepancy, because it shapes how much weight anything else deserves. Search 5-Amino-1MQ dosage and you will find two sets of numbers that cannot both be describing the same exposure. Oral capsule vendors describe 50 to 75 mg per day. Injectable vial vendors describe 150 to 500 mcg per day. That is a roughly 150-fold gap, and it is not explained by bioavailability alone.
The two figures come from different lineages. The milligram range is derived from allometric scaling of rodent dosing, where the compound was given orally. The microgram range appears borrowed from injectable peptide convention, which operates at that scale because peptides are receptor-active at very low concentrations. A small molecule enzyme inhibitor is not that kind of drug, and no published human pharmacokinetic study establishes what a microgram-scale subcutaneous dose achieves in tissue. Anyone presenting a single confident dose for 5-Amino-1MQ is presenting a convention, not a finding.
What 5-Amino-1MQ Actually Is
The full chemical name is 5-amino-1-methylquinolinium. Structurally it is a quinolinium ring with an amino group at the 5 position and a methyl group on the ring nitrogen, which gives it a permanent positive charge. It ships as a powder, and depending on the vendor it arrives as loose powder, capsules, or a lyophilized vial intended for reconstitution.
It has no amino acid sequence and no peptide bonds. It ended up in the peptide market because the same suppliers, research audience, and body composition interest carried it there. That matters practically: peptide vendors lean on HPLC purity and mass spectrometry identity for chains of amino acids, while for a quinolinium salt, identity confirmation and residual solvent data are the more relevant questions, and far fewer vendors publish them.
Its single documented mechanism is inhibition of NNMT. That enzyme takes nicotinamide, a form of vitamin B3, and attaches a methyl group borrowed from S-adenosylmethionine. The products are 1-methylnicotinamide and S-adenosylhomocysteine. Two things are consumed in the process: a NAD+ precursor and the cell's primary methyl donor.
In lean tissue this runs at a modest rate. In obesity, NNMT expression in white adipose tissue and liver is markedly elevated, and the byproduct 1-methylnicotinamide tracks upward with body mass and with insulin resistance. The proposed consequence is a fat cell that has less NAD+ available for the sirtuin and PARP enzymes that govern mitochondrial activity and fat oxidation, and therefore defaults toward storage. Suppress NNMT and, in theory, the precursor pool recovers and the cell shifts back toward burning.
This is the same destination that NAD+ precursor supplementation aims for by a different road. Precursors add raw material; NNMT inhibition reduces the drain. Our NAD+ guide covers the supply-side approach and where its own evidence is weaker than the marketing suggests.
5-Amino-1MQ is not approved as a drug in any jurisdiction. It is sold for laboratory research, and nothing below should be read as a protocol for personal use.
5-Amino-1MQ Benefits
The honest framing is that every claimed benefit traces to animal and cell data, and that the animal data is genuinely interesting. There are no controlled human trials. What follows separates the two.
Reduced fat mass without reduced food intake. This is the finding that built the compound's reputation and it is the strongest one. In diet-induced obese rodent models, suppressing NNMT lowered adipose mass while food intake stayed flat. The effect sizes reported in knockdown work were large enough to attract drug development interest, though the specific figures vary by model and are not directly translatable to people. That decoupling from appetite is what distinguishes the mechanism from GLP-1 style intervention, where intake falls first and body composition follows. Evidence grade: strong and reproducible in rodents, absent in humans.
Improved insulin sensitivity and glucose handling. Where metabolic disease is present, the enzyme tends to be more active in fat tissue, and the methylated byproduct it generates shows up at higher levels in people whose glucose control is worse. That association has been observed repeatedly in humans, but observing an association is not the same as testing an intervention, and the intervention half has only been done in animals, where blocking the enzyme improved glucose handling. Evidence grade: strong mechanistic and correlational support, no human intervention data.
Higher resting energy expenditure. Preclinical work points to increased basal metabolic activity in adipose tissue following NNMT inhibition, with upregulation of thermogenic gene expression. The realistic magnitude is modest. Nothing in the literature supports the "burns fat while you sit still" framing that appears on product pages. Evidence grade: mechanistically supported, magnitude unquantified.
Lean mass preservation. In rodent studies fat loss occurred without a matching loss of lean tissue, which is the pattern caloric restriction typically fails to produce. The proposed reason is tissue selectivity: the enzyme is abundant in fat and liver and sparse in muscle, so an inhibitor has far less to act on in muscle in the first place. This is plausible and consistent with the data, but it is an inference from expression patterns rather than a directly demonstrated sparing effect. Evidence grade: suggestive, indirect.
Longevity and sirtuin signaling. Restoring NAD+ availability supports sirtuin activity, and sirtuins sit at the center of most cellular aging models. This is where claims run furthest ahead of data. A mechanism that touches a longevity pathway is not a longevity effect. Evidence grade: speculative.
For comparison, the fat loss compounds that work by direct lipolytic signaling operate on an entirely different axis. AOD-9604 is a growth hormone fragment that pushes triglycerides out of fat cells, while 5-Amino-1MQ changes what the cell does with its energy budget. MOTS-c is closer conceptually, since it also targets metabolic flexibility, but it does so through AMPK rather than through NAD+ availability.
5-Amino-1MQ Side Effects
This section is short because the data is thin, and padding it would misrepresent the situation. There is no human safety trial. What exists is animal toxicology at research doses and unstructured self-reports from people using it outside any research setting.
Reported in practice:
- Mild gastrointestinal upset with oral dosing, most often nausea, more common at the upper end of the milligram range and when taken on an empty stomach.
- Injection site redness or transient soreness with the subcutaneous form, which is a property of subcutaneous injection generally rather than of this compound.
- Sleep disturbance and a stimulant-like restlessness are occasionally mentioned. There is no mechanistic explanation for this and no way to separate it from expectation effects.
Plausible on mechanism, not documented:
- Methylation cycle disruption. NNMT consumes SAM, so inhibiting it changes methyl group flow. Whether that produces a meaningful shift in homocysteine, neurotransmitter synthesis, or gene methylation at research doses is unknown. It is the most biologically coherent concern on this list and the least studied.
- Interactions with methylation-dependent medications, including some antidepressants and folate-pathway agents. No formal interaction study has been conducted on this compound.
- Hepatic considerations, since liver NNMT activity is part of normal nicotinamide handling.
What is not established either way: NNMT is not a single-purpose fat enzyme. It appears in cancer biology, neurodegeneration, and inflammatory signaling, and its role differs by tissue and context. Suppressing it over months has not been characterized in any species at the timescales people actually use. Preclinical studies have not flagged major organ toxicity at research doses, which is reassuring as far as it goes, but rodent toxicology at fixed doses over weeks is not a human safety profile.
5-Amino-1MQ Dosage Chart
Everything below reflects ranges reported in preclinical work and in researcher community protocols. These are observations about what has been used, not recommendations, and the oral and injectable columns should be read as separate conventions rather than as convertible equivalents.
| Goal or context | Reported range | Frequency | Typical cycle |
|---|---|---|---|
| Oral, conservative start | 25 mg per day | Once daily | First 1 to 2 weeks, then reassess |
| Oral, most commonly cited | 50 to 75 mg per day | Once daily or split into two doses | 8 to 12 weeks |
| Oral, upper end reported | Up to 100 mg per day | Split dosing more common at this level | Shorter blocks, least characterized |
| Injectable, beginner convention | 150 mcg per day | Once daily subcutaneous | 8 to 12 weeks |
| Injectable, intermediate | 250 to 350 mcg per day | Once daily subcutaneous | 8 to 12 weeks |
| Injectable, upper end reported | Up to 500 mcg per day | Once daily subcutaneous | 8 to 12 weeks |
| Off period between cycles | Not applicable | Not applicable | Minimum 4 weeks, commonly matched to cycle length |
Timing appears not to matter much: oral doses are taken with or without food, and no evidence establishes that time of day changes outcomes. Split dosing is usually justified by half-life, but human half-life for this compound has not been published, so the practice rests on convention rather than pharmacokinetics.
Cycling at 8 to 12 weeks with a 4-week break is universal in community protocols and universal in having no experimental basis. It is a precautionary default borrowed from peptide practice and applied to a compound whose long-term suppression profile is unknown. Reasonable instinct, but caution rather than a validated schedule. Treat the wide reported range as a measure of how unsettled this is, not as a menu.
Storage and Reconstitution
Handling depends entirely on which form arrives. Capsules and loose powder need nothing beyond a cool, dark, dry place away from humidity. Unlike most research peptides, 5-Amino-1MQ does not require refrigeration in its dry state, which is a consequence of being a stable small-molecule salt rather than a foldable chain of amino acids.
The lyophilized injectable form follows standard practice: reconstitute with bacteriostatic water, add the diluent slowly against the vial wall rather than directly onto the powder, swirl rather than shake, and refrigerate afterward. Reconstituted material is generally treated as good for a few weeks refrigerated. Because no published stability study covers this compound in solution, that window is inherited convention rather than a tested figure.
Stacking
Only two combinations have any real rationale, and neither has human data behind it.
The pairing with a direct lipolytic agent such as AOD-9604 is mechanistically non-overlapping: one mobilizes stored triglycerides, the other alters the metabolic state of the cell storing them. That is a coherent argument on paper. No study has tested the combination in any species.
Pairing with growth hormone secretagogues is the other commonly described stack, on the reasoning that GH-driven lipolysis and NNMT inhibition act through separate pathways. The same caveat applies, with the added complication that GH axis manipulation carries its own monitoring requirements.
Combining it with NAD+ precursors is often suggested and is the least well-reasoned of the three. Both target the same endpoint from opposite directions, and whether that is additive, redundant, or self-limiting has not been examined.
How to Verify What You Buy
Because 5-Amino-1MQ is a small molecule sold in a market built around peptides, generic peptide COAs often do not test the right things, and identity confirmation matters more than a headline purity number. Ask specifically for identity data on the quinolinium salt and check that the certificate names this compound rather than a peptide template. Our where to buy 5-Amino-1MQ breakdown covers which suppliers publish usable documentation, and the 5-Amino-1MQ for sale page tracks current listings and formats.
Frequently Asked Questions
What does 5-Amino-1MQ do?
It inhibits NNMT, an enzyme concentrated in white adipose tissue and liver that consumes nicotinamide and SAM. Suppressing it is proposed to preserve NAD+ precursor availability inside fat cells, which in rodent models shifts those cells toward higher energy expenditure and lower fat storage. Every documented effect comes from animal or cell research.
Is 5-Amino-1MQ a peptide?
No. It is a small molecule, 5-amino-1-methylquinolinium, with no amino acid sequence and no peptide bonds. It is sold alongside peptides and often labeled as one, which is a market convention rather than an accurate description.
Is 5-Amino-1MQ safe?
Human safety has not been established, because no human clinical trial has been published. Animal studies at research doses have not shown major organ toxicity. The most coherent open question is what sustained NNMT inhibition does to methylation, since the enzyme consumes the body's main methyl donor and NNMT has functions beyond fat metabolism.
How much 5-Amino-1MQ is typically used in research?
Reported oral protocols cluster at 50 to 75 mg per day with 25 mg used as a starting point, while injectable conventions run 150 to 500 mcg per day. These two ranges come from different sources and have never been reconciled in published pharmacokinetic work. Both are reported practice, not established dosing.
Is 5-Amino-1MQ legal?
It is not a controlled substance under US federal law and is not DEA scheduled. It is sold legally for research purposes. It is not FDA approved for human use, and marketing it for human consumption is not permitted. Regulatory status varies by country and should be checked locally.
